Analystreport

Acasti Pharma Inc. (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $2.50 price target on the stock.

Acasti Pharma, Inc. - Class A  (ACST) 
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors